• 5122 Citations
  • 30 h-Index
1991 …2019
If you made any changes in Pure these will be visible here soon.

Research Output 1991 2019

  • 5122 Citations
  • 30 h-Index
  • 125 Article
  • 2 Review article
2019

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms

Mózes, R., Gángó, A., Sulák, A., Vida, L., Reiniger, L., Timár, B., Krenács, T., Alizadeh, H., Masszi, T., Gaál-Weisinger, J., Demeter, J., Csomor, J., Matolcsy, A., Kajtár, B. & Bödör, C., Jan 1 2019, (Accepted/In press) In : Pathology.

Research output: Contribution to journalArticle

Calreticulin
Immunohistochemistry
Mutation
Neoplasms
Essential Thrombocythemia

Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning

Tordai, A., Bors, A., Kiss, K. P., Balassa, K., Andrikovics, H., Batai, A., Szilvasi, A., Rajczy, K., Inotai, D., Torbagyi, E., Lengyel, L., Barta, A., Remenyi, P. & Masszi, T., Jan 1 2019, In : PloS one. 14, 6, e0218945.

Research output: Contribution to journalArticle

Open Access
Transplants
Hematologic Neoplasms
Stem cells
cell transplantation
Tissue Donors

Effectiveness of intra-arterial steroid administration for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease

Bérczi, V., Tóth, A., Tatai, G., Fábián, J., Reményi, P. & Masszi, T., Jan 1 2019, (Accepted/In press) In : Clinical Radiology.

Research output: Contribution to journalArticle

Graft vs Host Disease
Steroids
Therapeutics
Inferior Mesenteric Artery
Superior Mesenteric Artery

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia

on behalf of the Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation, Jan 1 2019, In : British Journal of Haematology.

Research output: Contribution to journalArticle

Stem Cell Transplantation
Acute Myeloid Leukemia
Leukemia
Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Lovas, S., Varga, G., Farkas, P., Masszi, T., Wohner, N., Bereczki, Á., Adamkovich, N., Borbényi, Z., Szomor, Á., Alizadeh, H., Szaleczky, E., Wolf, K., Schneider, T., Plander, M., Szendrei, T., Csacsovszki, O., Csukly, Z., Rajnics, P., Egyed, M., Nagy, Z. & 4 others, Rejtő, L., Illés, A., Mikala, G. & Váróczy, L., Jan 1 2019, In : International Journal of Hematology.

Research output: Contribution to journalArticle

Multiple Myeloma
Safety
Disease-Free Survival
Kidney
Therapeutics
2018
3 Citations (Scopus)

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT

Giebel, S., Labopin, M., Potter, M., Poiré, X., Sengeloev, H., Socié, G., Huynh, A., Afanasyev, B. V., Schanz, U., Ringden, O., Kalhs, P., Beelen, D. W., Campos, A. M., Masszi, T., Canaani, J., Mohty, M. & Nagler, A., Jun 1 2018, In : European Journal of Cancer. 96, p. 73-81 9 p.

Research output: Contribution to journalArticle

Hematopoietic Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Unrelated Donors
Leukemia
Tissue Donors
20 Citations (Scopus)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Ross, D. M., Masszi, T., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., Le Coutre, P. D., Martino, B., Saussele, S., Giles, F. J., Radich, J. P., Saglio, G., Deng, W., Krunic, N., Bédoucha, V., Gopalakrishna, P. & Hochhaus, A., Feb 22 2018, (Accepted/In press) In : Journal of Cancer Research and Clinical Oncology. p. 1-10 10 p.

Research output: Contribution to journalArticle

Leukemia, Myeloid, Chronic Phase
Therapeutics
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease Progression
2 Citations (Scopus)

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

Kiladjian, J. J., Guglielmelli, P., Griesshammer, M., Saydam, G., Masszi, T., Durrant, S., Passamonti, F., Jones, M., Zhen, H., Li, J., Gadbaw, B., Perez Ronco, J., Khan, M. & Verstovsek, S., Apr 1 2018, In : Annals of Hematology. 97, 4, p. 617-627 11 p.

Research output: Contribution to journalArticle

Interferons
Safety
Hydroxyurea
Polycythemia Vera
Phlebotomy
2 Citations (Scopus)

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)

Schneider, T., Rosta, A., Losonczy, H., Radványi, G., Ujj, G., Egyed, M., Illés, A., Jakucs, J., Szerafin, L., Gasztonyi, Z., Masszi, T., Iványi, J., Demeter, J., Dombi, P., Tóth, A. & Borbényi, Z., Apr 1 2018, In : Pathology and Oncology Research. 24, 2, p. 199-205 7 p.

Research output: Contribution to journalArticle

Follicular Lymphoma
Disease-Free Survival
Therapeutics
Survival
Controlled Clinical Trials
4 Citations (Scopus)

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Viviani, S., Bachanova, V., Sureda, A., McClendon, T., Lee, C., Lisano, J. & Sweetenham, J., Dec 20 2018, In : Blood. 132, 25, p. 2639-2642 4 p.

Research output: Contribution to journalArticle

Hodgkin Disease
Disease-Free Survival
Recurrence
Placebos
Confidence Intervals
4 Citations (Scopus)

High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party

Akhtar, S., Montoto, S., Boumendil, A., Finel, H., Masszi, T., Jindra, P., Nemet, D., Fuhrmann, S., Beguin, Y., Castagna, L., Ferrara, F., Capria, S., Malladi, R., Moraleda, J. M., Bloor, A., Ghesquières, H., Meissner, J., Sureda, A. & Dreger, P., Jan 1 2018, In : American Journal of Hematology. 93, 1, p. 40-46 7 p.

Research output: Contribution to journalArticle

Stem Cell Transplantation
Hodgkin Disease
Lymphoma
Retrospective Studies
Transplantation
4 Citations (Scopus)

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT

Gagelmann, N., Eikema, D. J., Iacobelli, S., Koster, L., Nahi, H., Stoppa, A. M., Masszi, T., Caillot, D., Lenhoff, S., Udvardy, M., Crawley, C., Arcese, W., Mariette, C., Hunter, A., Leleu, X., Schipperus, M., Delforge, M., Pioltelli, P., Snowden, J. A., Itälä-Remes, M. & 4 others, Musso, M., van Biezen, A., Garderet, L. & Kröger, N., Apr 30 2018, In : Haematologica. 103, 5, p. 890-897 8 p.

Research output: Contribution to journalArticle

Stem Cell Transplantation
Multiple Myeloma
Neoplasms
Transplantation
Survival
1 Citation (Scopus)

Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature

Varga, G., Mikala, G., Gopcsa, L., Csukly, Z., Kollai, S., Balázs, G., Botond, T., Wohner, N., Horváth, L., Szombath, G., Farkas, P. & Masszi, T., Apr 23 2018, In : Journal of Oncology. 2018, 3970169.

Research output: Contribution to journalReview article

Multiple Myeloma
Central Nervous System
Plasma Cell Leukemia
Clonal Evolution
Therapeutics
11 Citations (Scopus)

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Leleu, X., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., Maisnar, V., Samoilova, O., Rosiñol, L., Langer, C., Song, K., Izumi, T., Cleeland, C., Berg, D., Lin, H. M., Zhu, Y., Skacel, T., Moreau, P. & Richardson, P. G., Aug 1 2018, In : American Journal of Hematology. 93, 8, p. 985-993 9 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Placebos
Quality of Life
Therapeutics

Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies

Balassa, K., Andrikovics, H., Remenyi, P., Batai, A., Szilvasi, A., Bors, A., Kiss, K. P., Rajczy, K., Inotai, D., Torbagyi, E., Lengyel, L., Barta, A., Gopcsa, L., Tordai, A. & Masszi, T., Jan 1 2018, In : Human Immunology. 79, 1, p. 13-19 7 p.

Research output: Contribution to journalArticle

Hematopoietic Stem Cell Transplantation
Tissue Donors
Survival
Neoplasms
Transplantation

Skin-homing CD8+ T cells preferentially express GPI-anchored peptidase inhibitor 16, an inhibitor of cathepsin K

Lupsa, N., Érsek, B., Horváth, A., Bencsik, A., Lajkó, E., Silló, P., Oszvald, Á., Wiener, Z., Reményi, P., Mikala, G., Masszi, T., Búzás, E. & Pós, Z., Dec 1 2018, In : European Journal of Immunology. 48, 12, p. 1944-1957 14 p.

Research output: Contribution to journalArticle

Cathepsin K
Protease Inhibitors
Skin
Graft vs Host Disease
Granzymes

The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma

Kiss, K. P., Varga, G., Mikala, G., Balassa, K., Bors, A., Kovy, P., Meggyesi, N., Kozma, A., Csacsovszki, O., Remenyi, P., Valyi-Nagy, I., Tordai, A., Masszi, T. & Andrikovics, H., Mar 4 2018, In : Leukemia and Lymphoma. 59, 3, p. 710-716 7 p.

Research output: Contribution to journalArticle

Clinical Protocols
Multiple Myeloma
Oncogenes
Proteasome Inhibitors
Genes
2017
18 Citations (Scopus)

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment

Dimopoulos, M. A., Stewart, A. K., Masszi, T., Spicka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A., San-Miguel, J., Ludwig, H., Ro, S., Aggarwal, S., Moreau, P. & Palumbo, A., Jan 1 2017, In : Blood Cancer Journal. 7, 4, e554.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Thalidomide
Disease-Free Survival
Therapeutics
1 Citation (Scopus)

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

Harrison, C. N., Griesshammer, M., Miller, C., Masszi, T., Passamonti, F., Zachee, P., Durrant, S., Pane, F., Guglielmelli, P., Verstovsek, S., Jones, M. M., Hunter, D. S., Sun, W., Li, J., Khan, M., Habr, D. & Kiladjian, J. J., Jan 1 2017, (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

Polycythemia Vera
INCB018424
16 Citations (Scopus)

Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

Mateos, M. V., Masszi, T., Grzasko, N., Hansson, M., Sandhu, I., Pour, L., Viterbo, L., Jackson, S. R., Stoppa, A. M., Gimsing, P., Hamadani, M., Borsaru, G., Berg, D., Lin, J., Di Bacco, A., Van De Velde, H., Richardson, P. G. & Moreau, P., Sep 30 2017, In : Haematologica. 102, 10, p. 1767-1775 9 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Placebos
Safety
Therapeutics
24 Citations (Scopus)

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Avet-Loiseau, H., Bahlis, N. J., Chng, W. J., Masszi, T., Viterbo, L., Pour, L., Ganly, P., Palumbo, A., Cavo, M., Langer, C., Pluta, A., Nagler, A., Kumar, S., Ben-Yehuda, D., Rajkumar, S. V., San-Miguel, J., Berg, D., Lin, J., Van De Velde, H., Esseltine, D. L. & 3 others, di Bacco, A., Moreau, P. & Richardson, P. G., Dec 14 2017, In : Blood. 130, 24, p. 2610-2618 9 p.

Research output: Contribution to journalArticle

Refractory materials
Disease-Free Survival
Chromosome Aberrations
Placebos
Hazards
21 Citations (Scopus)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

Kumar, S., Moreau, P., Hari, P., Mateos, M. V., Ludwig, H., Shustik, C., Masszi, T., Spencer, A., Hájek, R., Romeril, K., Avivi, I., Liberati, A. M., Minnema, M. C., Einsele, H., Lonial, S., Berg, D., Lin, J., Gupta, N., Esseltine, D. L. & Richardson, P. G., Aug 1 2017, In : British Journal of Haematology. 178, 4, p. 571-582 12 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Placebos
Thrombocytopenia
Proteasome Inhibitors
1 Citation (Scopus)

Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma

Varga, G., Mikala, G., Kiss, K. P., Kosóczki, É., Szabó, E., Meggyesi, N., Balassa, K., Kövy, P., Tegze, B., Szombath, G., Tordai, A., Andrikovics, H., Homolya, L. & Masszi, T., Nov 1 2017, In : Clinical Lymphoma, Myeloma and Leukemia. 17, 11, p. 734-742 9 p.

Research output: Contribution to journalArticle

Proteasome Endopeptidase Complex
Multiple Myeloma
Alleles
Disease-Free Survival
Genotype
2016
1 Citation (Scopus)

A krónikus myeloid leukaemia korszerũ diagnosztikája és kezelése

Translated title of the contribution: Chronic myelogenous leukemia: Diagnosis and treatmentDemeter, J., Poros, A., Bödör, C., Horváth, L. & Masszi, T., Sep 1 2016, In : Orvosi Hetilap. 157, 37, p. 1459-1468 10 p.

Research output: Contribution to journalReview article

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Chromosomes, Human, Pair 22
Chromosomes, Human, Pair 9
Hungary
50 Citations (Scopus)

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Hájek, R., Masszi, T., Petrucci, M. T., Palumbo, A., Rosiñol, L., Nagler, A., Yong, K. L., Oriol, A., Minarik, J., Pour, L., Dimopoulos, M. A., Maisnar, V., Rossi, D., Kasparu, H., van Droogenbroeck, J., Yehuda, D. B., Hardan, I., Jenner, M., Calbecka, M., Dávid, M. & 12 others, de la Rubia, J., Drach, J., Gasztonyi, Z., Górnik, S., Leleu, X., Munder, M., Offidani, M., Zojer, N., Rajangam, K., Chang, Y. L., San-Miguel, J. F. & Ludwig, H., Jul 15 2016, (Accepted/In press) In : Leukemia.

Research output: Contribution to journalArticle

Multiple Myeloma
Cyclophosphamide
Adrenal Cortex Hormones
Confidence Intervals
Survival
317 Citations (Scopus)

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A. & 11 others, Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S. & Chng, W. J., Jan 1 2016, In : The Lancet Oncology. 17, 1, p. 27-38 12 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Multicenter Studies
Intravenous Infusions
Random Allocation
49 Citations (Scopus)

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Avet-Loiseau, H., Fonseca, R., Siegel, D., Dimopoulos, M. A., Špička, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V., Mihaylov, G., Maisnar, V., Mateos, M. V., Wang, M., Niesvizky, R., Oriol, A., Jakubowiak, A., Minarik, J., Palumbo, A., Bensinger, W., Kukreti, V. & 4 others, Ben-Yehuda, D., Stewart, A. K., Obreja, M. & Moreau, P., Sep 1 2016, In : Blood. 128, 9, p. 1174-1180 7 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Cytogenetics
Disease-Free Survival
Dexamethasone
carfilzomib
20 Citations (Scopus)

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

Mesa, R., Verstovsek, S., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Zhen, H., Jones, M. M., Parasuraman, S., Li, J., Côté, I., Habr, D. & Vannucchi, A. M., Aug 1 2016, In : European Journal of Haematology. 97, 2, p. 192-200 9 p.

Research output: Contribution to journalArticle

Polycythemia Vera
Quality of Life
Symptom Assessment
Hydroxyurea
Pruritus
11 Citations (Scopus)

Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100

Krahling, T., Balassa, K., Kiss, K. P., Bors, A., Batai, A., Halm, G., Egyed, M., Fekete, S., Remenyi, P., Masszi, T., Tordai, A. & Andrikovics, H., Jan 1 2016, In : Cancer Epidemiology Biomarkers and Prevention. 25, 1, p. 98-104 7 p.

Research output: Contribution to journalArticle

Telomerase
Neoplasms
Therapeutics
Janus Kinase 2
Polycythemia Vera
406 Citations (Scopus)

Daratumumab, bortezomib, and dexamethasone for multiple myeloma

Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., Mark, T. M., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Spencer, A. & Sonneveld, P., Aug 25 2016, In : New England Journal of Medicine. 375, 8, p. 754-766 13 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Disease-Free Survival
Control Groups
Neutropenia
4 Citations (Scopus)

Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: Single-center experience of 18 years

Remenyi, P., Varga, G., Mikala, G., Reti, M., Gopcsa, L., Batai, A., Csukly, Z., Lengyel, L., Torbagyi, E., Barta, A., Fabian, J., Levai, D., Szombath, G., Andrikovics, H. & Masszi, T., Jan 1 2016, In : Transplantation Proceedings. 48, 1, p. 177-184 8 p.

Research output: Contribution to journalArticle

Stem Cell Transplantation
Multiple Myeloma
Interferons
Maintenance
Disease-Free Survival
52 Citations (Scopus)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the European ENEST1st study

Hochhaus, A., Rosti, G., Cross, N. C. P., Steegmann, J. L., Le Coutre, P., Ossenkoppele, G., Petrov, L., Masszi, T., Hellmann, A., Griskevicius, L., Wiktor-Jedrzejczak, W., Rea, D., Coriu, D., Brümmendorf, T. H., Porkka, K., Saglio, G., Gastl, G., Müller, M. C., Schuld, P., Di Matteo, P. & 5 others, Pellegrino, A., Dezzani, L., Mahon, F. X., Baccarani, M. & Giles, F. J., Jan 1 2016, In : Leukemia. 30, 1, p. 57-64 8 p.

Research output: Contribution to journalArticle

Leukemia, Myeloid, Chronic Phase
Clinical Trials
Therapeutics
Safety
Exanthema
26 Citations (Scopus)

Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma

Stewart, A. K., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Buchanan, J., Cocks, K., Yang, X., Xing, B., Zojwalla, N., Tonda, M., Moreau, P. & Palumbo, A., Nov 10 2016, In : Journal of Clinical Oncology. 34, 32, p. 3921-3930 10 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Quality of Life
Health Status
carfilzomib
2 Citations (Scopus)

Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia

Mátrai, Z., Andrikovics, H., Szilvási, A., Bors, A., Kozma, A., Ádám, E., Halm, G., Karászi, É., Tordai, A. & Masszi, T., Oct 18 2016, (Accepted/In press) In : Pathology and Oncology Research. p. 1-7 7 p.

Research output: Contribution to journalArticle

Lipoprotein Lipase
B-Cell Chronic Lymphocytic Leukemia
Survival
ROC Curve
Cytogenetics
375 Citations (Scopus)

Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma

TOURMALINE-MM1 Study Group, Apr 28 2016, In : New England Journal of Medicine. 374, 17, p. 1621-1634 14 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Placebos
Disease-Free Survival
lenalidomide
10 Citations (Scopus)

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

Ramsey, S. D., Nademanee, A., Masszi, T., Holowiecki, J., Abidi, M., Chen, A., Stiff, P., Viviani, S., Sweetenham, J. W., Radford, J., Zhu, Y., Bonthapally, V., Thomas, E., Richhariya, A., Hunder, N. N., Walewski, J. & Moskowitz, C. H., 2016, (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

Hematopoietic Stem Cells
Hodgkin Disease
Quality of Life
Transplants
Arm
3 Citations (Scopus)

Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

Balassa, K., Krahling, T., Remenyi, P., Batai, A., Bors, A., Kiss, K. P., Torbagyi, E., Gopcsa, L., Lengyel, L., Barta, A., Varga, G., Tordai, A., Masszi, T. & Andrikovics, H., Jul 7 2016, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-8 8 p.

Research output: Contribution to journalArticle

Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Haplotypes
Tissue Donors
Cytokines
76 Citations (Scopus)

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J. H., Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A. & 12 others, NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub-Agha, I., Duarte, R. F. & Carreras, E., May 16 2016, (Accepted/In press) In : Bone Marrow Transplantation.

Research output: Contribution to journalArticle

Hepatic Veno-Occlusive Disease
Transplantation
Bone Marrow
Cell Transplantation
Bone Marrow Transplantation
61 Citations (Scopus)

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Verstovsek, S., Vannucchi, A. M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Kirito, K., Besses, C., Hino, M., Moiraghi, B., Miller, C. B., Cazzola, M., Rosti, V., Blau, I., Mesa, R., Jones, M. M., Zhen, H. & 4 others, Li, J., Francillard, N., Habr, D. & Kiladjian, J. J., 2016, In : Haematologica. 101, 7, p. 821-829 9 p.

Research output: Contribution to journalArticle

Polycythemia Vera
Spleen
Therapeutics
Hydroxyurea
Hematocrit
2015
67 Citations (Scopus)

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Orlowski, R. Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., Goranova-Marinova, V., Dimopoulos, M. A., Cavenagh, J. D., Špička, I., Maiolino, A., Suvorov, A., Bladé, J., Samoylova, O., Puchalski, T. A., Reddy, M., Bandekar, R., van de Velde, H., Xie, H. & Rossi, J. F., Jan 1 2015, In : American Journal of Hematology. 90, 1, p. 42-49 8 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Interleukin-6
Placebos
Disease-Free Survival
Dexamethasone
147 Citations (Scopus)

Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study

O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., Bhat, G., Choi, M. R., Walewski, J., Savage, K., Foss, F., Allen, L. F. & Shustov, A., Aug 10 2015, In : Journal of Clinical Oncology. 33, 23, p. 2492-2499 8 p.

Research output: Contribution to journalArticle

Peripheral T-Cell Lymphoma
Disease-Free Survival
Drug Approval
Histone Deacetylase Inhibitors
belinostat
15 Citations (Scopus)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

Ludwig, H., Greil, R., Masszi, T., Spicka, I., Shpilberg, O., Hajek, R., Dmoszynska, A., Paiva, B., Vidriales, M. B., Esteves, G., Stoppa, A. M., Robinson, D., Chaturvedi, S., Ataman, O., Enny, C., Feng, H., van de Velde, H. & Viterbo, L., Nov 1 2015, In : British Journal of Haematology. 171, 3, p. 344-354 11 p.

Research output: Contribution to journalArticle

Thalidomide
Multiple Myeloma
Cyclophosphamide
Dexamethasone
Residual Neoplasm
285 Citations (Scopus)

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial

Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., Osmanov, D., Bachanova, V., Sweetenham, J., Sureda, A., Huebner, D., Sievers, E. L., Chi, A., Larsen, E. K., Hunder, N. N. & Walewski, J., May 9 2015, In : The Lancet. 385, 9980, p. 1853-1862 10 p.

Research output: Contribution to journalArticle

Stem Cell Transplantation
Hodgkin Disease
Placebos
Recurrence
Disease-Free Survival
560 Citations (Scopus)

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

ASPIRE Investigators, Jan 8 2015, In : New England Journal of Medicine. 372, 2, p. 142-152 11 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Control Groups
Disease-Free Survival
Confidence Intervals
Stem Cell Transplantation
Hodgkin Disease
Placebos
Recurrence
Therapeutics
8 Citations (Scopus)

NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma

Varga, G., Mikala, G., Andrikovics, H., Koszarska, M., Balassa, K., Ádám, E., Kozma, A., Tordai, A. & Masszi, T., Mar 1 2015, In : British Journal of Haematology. 168, 5, p. 679-688 10 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Disease-Free Survival
Alleles
NF-kappa B
Fluorescence In Situ Hybridization
14 Citations (Scopus)

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

Khoury, H. J., Cortes, J., Baccarani, M., Wetzler, M., Masszi, T., Digumarti, R., Craig, A., Benichou, A. C. & Akard, L., Jan 1 2015, In : Leukemia and Lymphoma. 56, 1, p. 120-127 8 p.

Research output: Contribution to journalArticle

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Cytogenetics
Leukemia, Myeloid, Accelerated Phase
Blast Crisis
31 Citations (Scopus)

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia

Stone, R. M., Mazzola, E., Neuberg, D., Allen, S. L., Pigneux, A., Stuart, R. K., Wetzler, M., Rizzieri, D., Erba, H. P., Damon, L., Jang, J. H., Tallman, M. S., Warzocha, K., Masszi, T., Sekeres, M. A., Egyed, M., Horst, H. A., Selleslag, D., Solomon, S. R., Venugopal, P. & 2 others, Lundberg, A. S. & Powell, B., Mar 20 2015, In : Journal of Clinical Oncology. 33, 11, p. 1252-1257 6 p.

Research output: Contribution to journalArticle

amonafide
Daunorubicin
Cytarabine
Dilatation and Curettage
Acute Myeloid Leukemia
233 Citations (Scopus)

Ruxolitinib versus standard therapy for the treatment of polycythemia vera

Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., He, S., Jones, M. M., Garrett, W., Li, J., Pirron, U., Habr, D. & Verstovsek, S., Jan 1 2015, In : New England Journal of Medicine. 372, 5, p. 426-435 10 p.

Research output: Contribution to journalArticle

Polycythemia Vera
Hydroxyurea
Hematocrit
Therapeutics
Janus Kinase 1
79 Citations (Scopus)

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial

Pardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A. M., Drummond, M. W., Jurgutis, M., Kuliczkowski, K., Gheorghita, E., Passamonti, F., Neumann, F., Patki, A., Gao, G. & Tefferi, A., Aug 1 2015, In : JAMA oncology. 1, 5, p. 643-651 9 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Randomized Controlled Trials
Safety
Essential Thrombocythemia
Polycythemia Vera